BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24405639)

  • 1. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.
    Guillaumet-Adkins A; Richter J; Odero MD; Sandoval J; Agirre X; Catala A; Esteller M; Prósper F; Calasanz MJ; Buño I; Kwon M; Court F; Siebert R; Monk D
    J Hematol Oncol; 2014 Jan; 7():4. PubMed ID: 24405639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
    Tao YF; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Xu LX; Li ZH; Wang NN; Du XJ; Sun LC; Zhao H; Fang F; Su GH; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    Int J Mol Med; 2014 Dec; 34(6):1505-15. PubMed ID: 25319049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on DNA methylation status of WT1 gene in its promoter region in hematologic malignancy cell lines].
    Zhao Y; Chen ZX; Hu SY; Cen JN; Gu WY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):517-20. PubMed ID: 16468326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
    Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
    Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
    Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
    Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells.
    Vidovic K; Svensson E; Nilsson B; Thuresson B; Olofsson T; Lennartsson A; Gullberg U
    Leukemia; 2010 May; 24(5):992-1000. PubMed ID: 20237505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
    Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
    Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
    Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
    Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation.
    Campo Dell'Orto M; Banelli B; Giarin E; Accordi B; Trentin L; Romani M; te Kronnie G; Basso G
    Oncol Rep; 2007 Aug; 18(2):417-23. PubMed ID: 17611665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
    Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
    Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.
    Woehlecke C; Wittig S; Arndt C; Gruhn B
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):523-9. PubMed ID: 25238704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.
    Scardocci A; Guidi F; D'Alo' F; Gumiero D; Fabiani E; Diruscio A; Martini M; Larocca LM; Zollino M; Hohaus S; Leone G; Voso MT
    Br J Cancer; 2006 Oct; 95(8):1108-13. PubMed ID: 17047656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.
    Gaiger A; Schmid D; Heinze G; Linnerth B; Greinix H; Kalhs P; Tisljar K; Priglinger S; Laczika K; Mitterbauer M; Novak M; Mitterbauer G; Mannhalter C; Haas OA; Lechner K; Jäger U
    Leukemia; 1998 Dec; 12(12):1886-94. PubMed ID: 9844919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
    Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
    Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.